A study in Diabetes Care showed that the use of continuous glucose monitoring had an incremental cost-effectiveness ratio of $98,108/quality-adjusted life year and resulted in reductions in A1C, daily test strip use and daily rate of non-severe hypoglycemia events among type 1 diabetes patients with an A1C of at least 7.5%, compared with the control group. Researchers used a cohort of 158 patients and found that both groups had similar QALY over six months.
Research examines cost-effectiveness of CGM in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.